Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTA01 and SCTA01C in COVID-19 outpatients
NCT05156645Phase 2Withdrawn
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SCTA01 and SCTA01C+SOC with Placebo+SOC (2 arms). Primary endpoints: Proportion of participants who experience COVID-19 related hospitalization or death at Day 29 and Proportion of patients with Grade >=3 treatment related adverse event at Day 8. Planned start Jan 2022; status: withdrawn.
02
Drugs
upanovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05156645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156645.